Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 560Neoplasms 504Carcinoma, Non-Small-Cell Lung 421Prostatic Neoplasms 331Colorectal Neoplasms 315Lung Neoplasms 284Neoplasm Metastasis 238Leukemia, Myeloid, Acute 222Ovarian Neoplasms 206Pancreatic Neoplasms 196Multiple Myeloma 186Squamous Cell Carcinoma of Head and Neck 141Stomach Neoplasms 140Recurrence 140Brain Neoplasms 139Melanoma 134Carcinoma, Hepatocellular 132Endometrial Neoplasms 128Glioblastoma 126Precursor Cell Lymphoblastic Leukemia-Lymphoma 117Triple Negative Breast Neoplasms 116Hematologic Neoplasms 104Head and Neck Neoplasms 103Carcinoma, Renal Cell 102Urinary Bladder Neoplasms 99Lymphoma 99Sarcoma 96Glioma 96Esophageal Neoplasms 92Uterine Cervical Neoplasms 88

Interventions

Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphomatoid Papulosis × 90 days × Clear all
NCT03587844 2026-04-03

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
58 enrolled
Lymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡